Scott A Sands Selected Research

Apnea

11/2022	Targeted Genome Sequencing Identifies Multiple Rare Variants in Caveolin-1 Associated with Obstructive Sleep Apnea.
5/2022	Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility.
1/2022	Clinical polysomnographic methods for estimating pharyngeal collapsibility in obstructive sleep apnea.
1/2021	Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity.
1/2021	Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea.
1/2021	A randomized controlled trial of oxygen therapy for patients who do not respond to upper airway surgery for obstructive sleep apnea.
1/2020	Effect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea: A Randomized, Double-Blind Crossover Study.
1/2020	Angiotensin II-Type I Receptor Antagonism Does Not Influence the Chemoreceptor Reflex or Hypoxia-Induced Central Sleep Apnea in Men.
1/2019	Admixture mapping identifies novel loci for obstructive sleep apnea in Hispanic/Latino Americans.
1/2019	The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott A Sands Research Topics

Disease

26	Obstructive Sleep Apnea 05/2022 - 09/2012
19	Apnea 11/2022 - 12/2008
9	Sleep Apnea Syndromes (Sleep Apnea) 01/2022 - 01/2014
5	Heart Failure 01/2017 - 11/2011
4	Hypoxia (Hypoxemia) 01/2020 - 12/2009
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 04/2008
3	Central Sleep Apnea (Central Sleep Apnea Syndrome) 01/2020 - 09/2009
3	Multiple Sclerosis 10/2015 - 09/2014
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2015 - 09/2014
3	Myocardial Infarction 04/2008 - 09/2004
2	Premature Birth (Birth, Premature) 11/2021 - 06/2021
2	Globoid Cell Leukodystrophy (Krabbe Disease) 01/2019 - 11/2016
2	Asthma (Bronchial Asthma) 11/2013 - 05/2012
2	Cheyne-Stokes Respiration 03/2013 - 11/2011
2	Acute Coronary Syndrome 04/2008 - 01/2007
1	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2022
1	Mouth Breathing 01/2022
1	Sleepiness 01/2022
1	Obesity 01/2022
1	Infarction (Infarctions) 01/2022
1	Atherosclerosis 01/2022
1	Stroke (Strokes) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	COVID-19 01/2021
1	Hypercapnia 01/2021
1	Motor Disorders 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019
1	Seizures (Absence Seizure) 07/2017
1	Alzheimer Disease (Alzheimer's Disease) 10/2016
1	Inflammation (Inflammations) 08/2015
1	Dyspepsia (Indigestion) 09/2014
1	Weight Gain 09/2014
1	Autistic Disorder (Autism) 02/2014
1	Systolic Heart Failure 01/2014
1	Polyostotic Fibrous Dysplasia (McCune Albright Syndrome) 05/2013
1	Lung Diseases (Lung Disease) 06/2010

Drug/Important Bio-Agent (IBA)

9	Oxygen (Dioxygen)IBA 05/2022 - 12/2008
4	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 05/2022 - 01/2019
4	oxybutynin (Tavor)FDA LinkGeneric 05/2022 - 01/2019
4	IronIBA 10/2016 - 04/2014
3	Docosahexaenoic AcidsIBA 11/2021 - 04/2008
3	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 06/2021 - 09/2004
2	Muscarinic AntagonistsIBA 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 07/2017
2	salicylhydroxamic acid (SHAM)IBA 01/2019 - 08/2015
2	GalactosylceramidaseIBA 01/2019 - 11/2016
2	Desipramine (Pertofrane)FDA LinkGeneric 01/2017 - 02/2004
2	Acetazolamide (Diamox)FDA LinkGeneric 01/2014 - 02/2013
2	Bronchodilator Agents (Bronchodilators)IBA 11/2013 - 05/2012
2	LipidsIBA 04/2008 - 01/2007
1	Interleukin-6 (Interleukin 6)IBA 11/2021
1	Drug CombinationsIBA 01/2021
1	Polymethyl Methacrylate (Sol)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	SandIBA 01/2021
1	Angiotensin IIIBA 01/2020
1	Losartan (Cozaar)FDA LinkGeneric 01/2020
1	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 01/2020
1	Codon (Codons)IBA 01/2019
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2019
1	Oxyhemoglobins (Oxyhemoglobin)IBA 01/2019
1	Complement System Proteins (Complement)IBA 07/2018
1	Tiagabine (Gabitril)FDA Link 02/2017
1	Biological ProductsIBA 01/2017
1	Psychosine (Galactosylsphingosine)IBA 11/2016
1	Galactose (Galactopyranose)FDA LinkGeneric 11/2016
1	SphingosineIBA 11/2016
1	Carbon DioxideIBA 11/2016
1	GlycosphingolipidsIBA 11/2016
1	Galactosylceramides (Galactocerebrosides)IBA 11/2016
1	Hypnotics and Sedatives (Sedatives)IBA 11/2016
1	ParaffinIBA 10/2016
1	Coloring Agents (Dyes)IBA 10/2015
1	Iron Regulatory Protein 1IBA 10/2015
1	Transferrin Receptors (Transferrin Receptor)IBA 10/2015
1	SynaptophysinIBA 10/2015
1	LipopolysaccharidesIBA 08/2015
1	3-nitrotyrosineIBA 10/2014
1	Proteins (Proteins, Gene)FDA Link 10/2014
1	Peroxynitrous Acid (Peroxynitrite)IBA 10/2014
1	Proton Pump InhibitorsIBA 09/2014
1	AntacidsIBA 09/2014
1	Histamine H2 AntagonistsIBA 09/2014
1	Omeprazole (Prilosec)FDA LinkGeneric 09/2014
1	Messenger RNA (mRNA)IBA 02/2014
1	Oxytocin (Pitocin)FDA LinkGeneric 02/2014
1	Oxytocin Receptors (Oxytocin Receptor)IBA 02/2014
1	GTP-Binding Proteins (G-Protein)IBA 02/2014
1	Histamine (Histamine Dihydrochloride)FDA Link 05/2013
1	3,5-diisopropylsalicylic acid (DIPS)IBA 06/2010

Therapy/Procedure

15	Therapeutics 01/2021 - 06/2015
13	Continuous Positive Airway Pressure 01/2022 - 09/2009
4	Catheters 11/2019 - 09/2012
3	Precision Medicine 11/2022 - 01/2018
2	Occlusal Splints 01/2022 - 01/2021
1	Myocardial Revascularization 01/2022
1	Critical Care (Surgical Intensive Care) 01/2021
1	Intravenous Injections 01/2019
1	Intraperitoneal Injections 01/2019